NDI, GRAS and Supplement Safety Assessment

The objective of NDI and GRAS for supplements and foods is to provide a baseline evaluation of the safety aspects of an ingredient.

FDA issued draft guidance on the NDI and final guidance on the updated GRAS requirement in August 2016. The guidances are likely to require a significant amount of information related to safety and quality of dietary ingredients to be compiled and evaluated by scientific experts.

Four Steps to Compliance:

1. Determine the most likely regulatory status of your ingredient: ODI, NDI, GRAS or other based on a preliminary review of regulatory status and toxicology data.

2. Compile a master file of all your safety and quality documents supporting the new CFR 117 and the new FDA guidances. Most master files are more than a hundred pages long, including references.

3. Have the master file reviewed for gaps according to the regulatory status. Perform a risk assessment to safety, quality or brand presented from the analysis.

4. Chart a plan of action to meet the requirements.

Toxicology and safety studies are expensive to conduct, so you need to know if your ingredients need to go through the new GRAS Notification process, require a NDI Notification, and also carry any specific risk for adulteration or contamination. Take care of these elements, and you can be fairly sure that you will not be blind sided by regulators, consumers, or class action attorneys.

A pre-assessment is typically conducted quickly to determine the appropriate strategy and level of risk. Contact us to determine the best strategy for you.

—————————-

For more detail, here is a framework of basic requirements for a safety assessment

Clinical, Medicinal and Food Use
1. In country to market
2. Global
Regulatory Status
1. ODI or NDI (if ingredient used for supplement)
2. GRAS
3. Other
Toxicity Summary
1. History of human consumption in foods/supplements including dosage amount and composition
2. LD50/acute toxicity/chronic/subchronic toxicity studies
3. Bioavailability and ADME
4. Clinical trials
5. Other (genotoxicity, carcinogenicity, reproductive toxicity etc)
6. Case reports, AER and Drug Interaction Review
Dietary Supplement Manufacturing Risk Review (or CMC, Chemistry/Manufacturing/Control)
1. Chemical and Nutritional Characterization
  1. Literature review
  2. Specification, Certificate of Analysis, ID and contaminants
2. Manufacturing Facility GMP evaluation (self-assessment and audits)
3. Potential adulterants and their controls

NDI, GRAS and Supplement Safety Assessment

NDI, GRAS and Supplement Safety Assessment

About the Author: NaturPro